Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2234429 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14CA12GRIK1GRIK2 | |
| SCHEMBL293294 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14CA12GRIK1GRIK2 | |
| SCHEMBL295878 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14CA12GRIK1GRIK2 | |
| SCHEMBL293293 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14CA12GRIK1GRIK2 | |
| SCHEMBL2234435 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14CA12GRIK1GRIK2 | |
| SCHEMBL8090761 | 0.87 | SMN1; SMN2 (0.44) | SMN1; SMN2CA14CA12MEN1KMT2A | |
| SCHEMBL9978358 | 0.82 | ALDH1A1 (0.34) | GRIK1GRIK2CYP2C9 | |
| SCHEMBL9978359 | 0.82 | ALDH1A1 (0.34) | GRIK1GRIK2CYP2C9 | |
| SCHEMBL9978356 | 0.82 | ALDH1A1 (0.34) | GRIK1GRIK2CYP2C9 | |
| SCHEMBL9978585 | 0.82 | ALDH1A1 (0.34) | GRIK1GRIK2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011148392-A1 | PROCESS FOR THE PREPARATION OF (2S,4S,5S,7S)-N-(2-CARBAMYL-2- METHYLPROPYL)-5-AMINO-4-HYDROXY-2,7-DIISOPROPYL-8-[4-METHOXY-3-(3- METHOXYPROPOXY)PHENYL]-OCTANAMIDE HEMIFUMARATE AND ITS INTERMEDIATES THEREOF | MSN LABORATORIES LIMITED (IN) | 2011-12-01 | — | — | WO | claimed |
| EP-2171061-B1 | PREPARATION OF AN ESTERASE | DPX HOLDINGS BV (NL) | 2017-09-27 | — | — | EP | disclosed |
| US-9309503-B2 | Preparation of an esterase | DPX HOLDINGS B.V. (NL) | 2016-04-12 | — | — | US | disclosed |
| US-20130310577-A1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | DSM IP ASSETS B.V. (NL) | 2013-11-21 | — | — | US | disclosed |
| US-8563279-B2 | Convergent synthesis of renin inhibitors and intermediates useful therein | DSM IP ASSETS B.V. (NL) | 2013-10-22 | — | — | US | disclosed |
| EP-2225200-B1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | DSM IP ASSETS BV (NL) | 2013-10-16 | — | — | EP | disclosed |
| US-8158393-B2 | Polypeptide having esterase activity and recombinant esterase and use thereof | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AU) | 2012-04-17 | — | — | US | disclosed |
| EP-1966373-B1 | Polypeptide having esterase activity and recombinant esterase and use thereof | DSM FINE CHEM AUSTRIA GMBH (AT) | 2012-03-14 | — | — | EP | disclosed |
| WO-2011148392-A1 | PROCESS FOR THE PREPARATION OF (2S,4S,5S,7S)-N-(2-CARBAMYL-2- METHYLPROPYL)-5-AMINO-4-HYDROXY-2,7-DIISOPROPYL-8-[4-METHOXY-3-(3- METHOXYPROPOXY)PHENYL]-OCTANAMIDE HEMIFUMARATE AND ITS INTERMEDIATES THEREOF | MSN LABORATORIES LIMITED (IN) | 2011-12-01 | — | — | WO | disclosed |
| US-20110177553-A1 | PREPARATION OF AN ESTERASE | DPX HOLDINGS B.V. (NL) | 2011-07-21 | — | — | US | disclosed |
| US-20110008852-A1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | JLL/DELTA DUTCH NEWCO B.V. (NL) | 2011-01-13 | — | — | US | disclosed |
| US-20100248337-A1 | PROCESS FOR THE PRODUCTION OF (s)-5-CHLORO-2-ISOPROPYLPENT-4-ENOIC ACID ESTERS | TAYLOR IAN N | 2010-09-30 | — | — | US | disclosed |
| EP-2225200-A1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | DSM IP Assets B.V. (NL) | 2010-09-08 | — | — | EP | disclosed |
| US-7759110-B2 | Process for the production of (S)-5-chloro-2-isopropylpent-4-enoic acid esters | TAYLOR IAN N | 2010-07-20 | — | — | US | disclosed |
| EP-2171061-A1 | PREPARATION OF AN ESTERASE | DSM IP Assets B.V. (NL) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009080773-A1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | DSM IP ASSETS B.V. (NL) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009004093-A1 | PREPARATION OF AN ESTERASE | DSM IP ASSETS B.V. (NL) | 2009-01-08 | — | — | WO | disclosed |
| US-20080131944-A1 | Process For the Production of (S)-5-Chloro-2-Ispropylpent-4-Enoic Acid Esters | TAYLOR IAN N | 2008-06-05 | — | — | US | disclosed |
| CN-1993476-A | Process for the preparation of -5-chloro-2-isopropylpent-4-enoic acid esters | DOW GLOBAL TECHNOLOGIES INC (US) | 2007-07-04 | — | — | CN | disclosed |
| EP-1626093-A1 | Process for the production of (S)-5-chloro-2-isopropylpent-4-enoic acid esters | DOW GLOBAL TECHNOLOGIES INC. (US) | 2006-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008852-A1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | REN, ACE, AGT | SMN1; SMN2 4665/4885CA14 406/4885CA12 998/4885 |
| US-20130310577-A1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | REN, ACE, AGT | SMN1; SMN2 4654/4885CA14 412/4885CA12 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.